Advertisement

Antidementiva

  • Ulrich Schwabe

Zusammenfassung

Größte Gruppe der Antidementiva sind die Cholinesterasehemmer gefolgt von Memantin, das aber nur etwa halb so viel verordnet wird. In beiden Gruppen überwiegen inzwischen die Generika. Traditionelle Antidementiva (Piracetam, Ginkgoextrakt, Nicergolin) ohne gesicherten Nutzen haben ihren rückläufigen Trend fortgesetzt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. AD2000 Collaborative Group (2004): Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363: 2105–2115Google Scholar
  2. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011): Alzheimer's disease. Lancet 377: 1019–1031PubMedCrossRefGoogle Scholar
  3. Bickel H (2001): Demenzen im höheren Lebensalter: Schätzungen des Vorkommens und der Versorgungskosten. Z Gerontol Geriat 34: 108–115CrossRefGoogle Scholar
  4. Birks J (2006): Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD00559–3Google Scholar
  5. Birks J, Grimley Evans J (2006): Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD00312–0Google Scholar
  6. Birks J, Harvey RJ (2006): Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25; (1): CD00119–0.Google Scholar
  7. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE (2009): Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2: CD00119–1Google Scholar
  8. Cummings J, Froelich L, Black SE, Bakchine S, Bellelli G, Molinuevo JL, Kressig RW, Downs P, Caputo A, Strohmaier C (2012): Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease. Dement Geriatr Cogn Disord 33: 341–353PubMedCrossRefGoogle Scholar
  9. Davies P, Maloney AJ (1976): Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2: 140–3Google Scholar
  10. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde, Deutsche Gesellschaft für Neurologie (2009): S3-Leitlinie Demenzen. Internet: www.dgn.org/images/stories/dgn/pdf/s3_leitlinie_demenzen.pdfGoogle Scholar
  11. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R; Alzheimer‘s Disease Cooperative Study Steering Committee; Solanezumab Study Group (2014): Phase 3 trials of solanezumab for mild-to-moderate Alzheimer‘s disease. N Engl J Med 370: 311–321Google Scholar
  12. Flicker L, Grimley Evans G (2001): Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev. 2001;(2):CD001011Google Scholar
  13. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA (2008): Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372: 216–223PubMedCrossRefGoogle Scholar
  14. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O‘Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P (2012): Donepezil and memantine for moderate-to-severe Alzheimer‘s disease. N Engl J Med 366: 893–903PubMedCrossRefGoogle Scholar
  15. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (2007): Nutzenbewertung von Cholinesterasehemmern bei Patienten mit Alzheimer Demenz, auch im Vergleich mit anderen Therapieoptionen. Im Internet unter: www.iqwig.de/download/A05-19A_Abschlussbericht_Cholinesterasehemmer_bei_Alzheimer_Demenz.pdf
  16. Loy C, Schneider L (2006): Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006 Jan 25; (1): CD00174–7Google Scholar
  17. McShane R, Areosa Sastre A, Minakaran N (2006): Memantine for dementia. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD00315–4Google Scholar
  18. Muayqil T, Camicioli R (2012): Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer‘s disease and other dementias. Dement Geriatr Cogn Dis Extra 2: 546–572PubMedCentralPubMedCrossRefGoogle Scholar
  19. National Institute for Health and Clinical Excellence (2011): NICE technology appraisal guidance 217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of NICE technology appraisal guidance 111). Internet: www.nice.org.uk/nicemedia/live/13419/ 53619/53619.pdfGoogle Scholar
  20. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kövari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG (2012): Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71: 362–381PubMedCentralPubMedCrossRefGoogle Scholar
  21. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ; Alzheimer‘s Disease Cooperative Study Group (2005): Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352: 2379–2388Google Scholar
  22. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M (2008): Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148: 379–397PubMedCrossRefGoogle Scholar
  23. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators (2014): Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer‘s disease. N Engl J Med 370: 322–333Google Scholar
  24. Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Andrieu S; GuidAge Study Group (2012): Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 11: 851–859Google Scholar
  25. Winblad B (2005): Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev 11: 169–182PubMedGoogle Scholar
  26. Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R (2007): A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer‘s disease–rivastigmine patch versus capsule. Int J Geriatr Psychiatry 22: 456–467PubMedGoogle Scholar
  27. Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, Mayorga AJ, Wang D, Brashear HR, Nye JS; The GAL-INT-11/18 Study Group (2008): Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 70: 2024–2035Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Ulrich Schwabe
    • 1
  1. 1.Pharmakologisches InstitutUniversität HeidelbergHeidelberg

Personalised recommendations